论文部分内容阅读
α_1抗胰蛋白酶(α_1AT)缺乏症是一种慢性遗传性疾病。使用人血浆α_1AT 经静脉注入,提高患者肺部功能性。α_1AT 水平,重建下呼吸道抗中性白细胞弹性酶保护性屏障,防止肺间质的进行性破坏。无论是每周、每月给药一次或进行血浆交换均可达到目的。使用人血浆α_1AT 或用现代生物技术生产的重组α_1AT 进行喷雾增补治疗是又一种有吸引力的新方法,患者可以自己进行治疗,减少了医药负担。未来的α_1AT 缺乏症的治疗将是基因治疗,它将是今后研究中活跃的课题。
α_1 antitrypsin (α_1AT) deficiency is a chronic genetic disease. Human plasma α_1AT is injected intravenously to improve lung function of patients. α_1AT levels, reconstruction of the lower respiratory tract anti-neutrophil elastase protective barrier to prevent the progressive destruction of interstitial lung. Whether it is weekly, once a month, or plasma exchange can be achieved. Spray refill treatment with human plasma α_1AT or recombinant α_1AT produced using modern biotechnology is another attractive new method that patients can treat on their own and reduce the medical burden. The future treatment of α_1AT deficiency will be gene therapy, which will be an active topic in future research.